Correlation Between ImmuPharma PLC and DG Innovate

Can any of the company-specific risk be diversified away by investing in both ImmuPharma PLC and DG Innovate at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ImmuPharma PLC and DG Innovate into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ImmuPharma PLC and DG Innovate PLC, you can compare the effects of market volatilities on ImmuPharma PLC and DG Innovate and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ImmuPharma PLC with a short position of DG Innovate. Check out your portfolio center. Please also check ongoing floating volatility patterns of ImmuPharma PLC and DG Innovate.

Diversification Opportunities for ImmuPharma PLC and DG Innovate

-0.71

Correlation Coefficient

ImmuPharma PLC  DG Innovate

Pay attention - limited upside

The 3 months correlation between ImmuPharma and DGI is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding ImmuPharma PLC and DG Innovate PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DG Innovate PLC and ImmuPharma PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ImmuPharma PLC are associated (or correlated) with DG Innovate. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DG Innovate PLC has no effect on the direction of ImmuPharma PLC i.e., ImmuPharma PLC and DG Innovate go up and down completely randomly.

Pair Corralation between ImmuPharma PLC and DG Innovate

Assuming the 90 days trading horizon ImmuPharma PLC is expected to under-perform the DG Innovate. But the stock apears to be less risky and, when comparing its historical volatility, ImmuPharma PLC is 1.5 times less risky than DG Innovate. The stock trades about -0.09 of its potential returns per unit of risk. The DG Innovate PLC is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  7.50  in DG Innovate PLC on September 14, 2024 and sell it today you would earn a total of  1.00  from holding DG Innovate PLC or generate 13.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

ImmuPharma PLC  vs.  DG Innovate PLC

ImmuPharma PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ImmuPharma PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

DG Innovate PLC

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in DG Innovate PLC are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady technical and fundamental indicators, DG Innovate exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with ImmuPharma PLC and DG Innovate

The main advantage of trading using opposite ImmuPharma PLC and DG Innovate positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ImmuPharma PLC position performs unexpectedly, DG Innovate can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DG Innovate will offset losses from the drop in DG Innovate's long position.

The idea behind ImmuPharma PLC and DG Innovate PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.